These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 11025593)

  • 1. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
    Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
    Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
    Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH; Anter AH; Awad IA
    Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
    Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
    Hoskin PJ; Lowry L; Horwich A; Jack A; Mead B; Hancock BW; Smith P; Qian W; Patrick P; Popova B; Pettitt A; Cunningham D; Pettengell R; Sweetenham J; Linch D; Johnson PW
    J Clin Oncol; 2009 Nov; 27(32):5390-6. PubMed ID: 19738111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
    Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
    Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
    J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.